Intravitreal aflibercept for neovascular age-related macular degeneration

Immunotherapy

Volumn 5, Issue 2, 2013, Pages 121-130

  Xu, David ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

aflibercept; macular degeneration; VEGF; VEGF Trap

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

ARTERIAL THROMBOEMBOLISM; ARTICLE; CATARACT; COLORECTAL CANCER; CONJUNCTIVAL HEMORRHAGE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE DISEASE; EYE PAIN; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CANCER; LASER COAGULATION; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEINURIA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING, COMPETITIVE; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EYE; HUMANS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874095884     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.158     Document Type: Article

References (76)

1. Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2(2), 165-175 (2010).
2. Ng EW, Shima DT, Calias P et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5(2), 123-132 (2006).
3. Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica 227(Suppl. 1), 11-20 (2012).
4. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37(9), 1929-1934 (1996).
5. Tolentino MJ, Miller JW, Gragoudas ES et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch. Ophthalmol. 114(8), 964-970 (1996).
6. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 81(2), 154-162 (1997).
7. Rakic JM, Lambert V, Devy L et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44(7), 3186-3193 (2003).
8. Krzystolik MG, Afshari MA, Adamis AP et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120(3), 338-346 (2002).
9. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest. Ophthalmol. Vis. Sci. 49(10), 4523-4527 (2010).
10. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11(7), 753-764 (2006).
11. Twardowski P, Stadler WM, Frankel P et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 76(4), 923-926 (2010).
12. Coleman RL, Sill MW, Lankes HA et al. A Phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 127(3), 538-543 (2012).
13. Gotlieb WH, Amant F, Advani S et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A Phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 13(2), 154-162 (2012).
14. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499-3506 (2012).
15. Tarhini AA, Frankel P, Margolin KA et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin. Cancer Res. 17(20), 6574-6581 (2011).
16. Resnikoff S, Pascolini D, Etya'ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82(11), 844-851 (2004).
17. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99(6), 933-943 (1992).
18. Friedman DS, O'Colmain BJ, Muñoz B et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4), 564-572 (2004).
19. Ferris FL, Davis MD, Clemons TE et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch. Ophthalmol. 123(11), 1570-1574 (2005).
20. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch. Ophthalmol. 121(4), 519-526 (2003).
21. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest. Ophthalmol. Vis. Sci. 36(1), 182-191 (1995).
22. Deangelis MM, Silveira AC, Carr EA, Kim IK. Genetics of age-related macular degeneration: current concepts, future directions. Semin. Ophthalmol. 26(3), 77-93 (2011).
23. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 45(2), 115-134 (2000).
24. Telander DG. Inflammation and age-related macular degeneration (AMD). Semin. Ophthalmol. 26(3), 192-197 (2011).
25. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch. Ophthalmol. 122(4), 598-614 (2004).
26. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch. Ophthalmol. 109(8), 1109-1114 (1991).
27. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch. Ophthalmol. 117(10), 1329-1345 (1999).
28. Lee JH, Canny MD, De Erkenez A et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl Acad. Sci. USA 102(52), 18902-18907 (2005).
29. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351(27), 2805-2816 (2004).
30. Chakravarthy U, Adamis AP, Cunningham ET Jr et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113(9), 1508.e1-1508.e25 (2006).
31. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997).
32. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112(6), 1035-1047 (2005).
33. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113(11), 2002.e1-2002.e12 (2006).
34. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch. Clin. Exp. Ophthalmol. 246(1), 81-87 (2008).
35. Tufail A, Patel PJ, Egan C et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 340, c2459 (2010).
36. Rich RM, Rosenfeld PJ, Puliafito CA et al. Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Retina (Phil.) 26(5), 495-511 (2006).
37. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3), 363.e5-372.e5 (2006).
38. Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina (Phil.) 26(4), 383-390 (2006).
39. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am. J. Ophthalmol. 151(5), 887.e1-895.e1 (2011).
40. Dhoot DS, Kaiser PK. Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther. 12(3), 371-381 (2012).
41. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419-1431 (2006).
42. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1432-1444 (2006).
43. Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1), 57.e5-65.e5 (2009).
44. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am. J. Ophthalmol. 150(3), 315.e1-324.e1 (2010).
45. Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am. J. Ophthalmol. 148(1), 43.e1-58.e1 (2009).
46. Schmidt-Erfurth U, Eldem B, Guymer R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118(5), 831-839 (2011).
47. Holz FG, Amoaku W, Donate J et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118(4), 663-671 (2011).
48. Singer MA, Awh CC, Sadda S et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119(6), 1175-1183 (2012).
49. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf. 9(1), 149-165 (2010).
50. Martin DF, Maguire MG, Ying G et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897-1908 (2011).
51. Martin DF, Maguire MG, Fine SL et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7), 1388-1398 (2012).
52. Chakravarthy U, Harding SP, Rogers CA et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7), 1399-1411 (2012).
53. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl Acad. Sci. USA 92(23), 10457-10461 (1995).
54. Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15(18), 4919-4927 (1996).
55. Wulff C, Wilson H, Rudge JS et al. Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap (A40). J. Clin. Endocrinol. Metab. 86(7), 3377-3386 (2001).
56. Wulff C, Wiegand SJ, Saunders PT, Scobie GA, Fraser HM. Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology 142(7), 3244-3254 (2001).
57. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99(17), 11393-11398 (2002).
58. Kim ES, Serur A, Huang J et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl Acad. Sci. USA 99(17), 11399-11404 (2002).
59. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem. Biophys. Res. Commun. 408(2), 276-281 (2011).
60. Huang J, Frischer JS, Serur A et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl Acad. Sci. USA 100(13), 7785-7790 (2003).
61. Byrne AT, Ross L, Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9(15), 5721-5728 (2003).
62. Cao J, Zhao L, Li Y et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest. Ophthalmol. Vis. Sci. 51(11), 6009-6017 (2010).
63. Saishin Y, Saishin Y, Takahashi K et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 195(2), 241-248 (2003).
64. Nguyen QD, Shah SM, Hafiz G et al. A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113(9), 1522.e1-1522.e14 (2006).
65. Nguyen QD, Shah SM, Browning DJ et al. A Phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 116(11), 2141.e1-2148.e1 (2009).
66. Brown DM, Heier JS, Ciulla T et al. Primary endpoint results of a Phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 118(6), 1089-1097 (2011).
67. Heier JS, Boyer D, Nguyen QD et al. The 1-year results of CLEAR-IT 2, a Phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 118(6), 1098-1106 (2011).
68. Heier JS, Brown DM, Chong V et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119(12), 2537-2548 (2012).
69. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 92(5), 667-668 (2008).
70. Papadopoulos N, Martin J, Ruan Q et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2), 171-185 (2012).
71. Jumper JM. PAT survey presentation. Presented at: American Society of Retina Specialists. Las Vegas, NV, USA, 30 August 2012.
72. Benz MS. The Superdose Anti-VEGF (SAVE) trial: 2.0-mg intravitreal ranibizumab for recalcitrant neovascular AMD. American Academy of Opthalmology 2011 Annual Meeting. Orlando, FL, USA, 22-25 October (Poster 493).
73. Major J. Pigment epithelial detachment improvement in non-naive neovascular AMD patients after intravitreal aflibercept. Presented at: American Society of Retina Specialists. Las Vegas, NY, USA, 27 August 2012.
74. Sharma A. Resolution of persistent macular edema, SRF and/or RPE detachment after single injection of aflibercept in patients with neovascular AMD. Presented at: American Society of Retina Specialists. Las Vegas, NY, USA, 27 August 2012.
75. Boyer D, Heier J, Brown DM et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the Phase 3 COPERNICUS study. Ophthalmology 119(5), 1024-1032 (2012).
76. Do DV, Nguyen QD, Schmidt-Erfurth U et al. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119(8), 1658-1665 (2012).